Please assess the completion status of the following clinical trial:

Trial Title: Study of Fruquintinib in Patients With Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥ 18 and ≤ 75 years of age , with ≥ 40 Kg~* Histological or cytological confirmed metastatic colorectal cancer~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Failed 2 or more lines of chemotherapy~* Adequate hepatic, renal, heart, and hematologic functions~* At least one measurable lesion (larger than 10 mm in diameter by spiral CT scan)~* Signed and dated informed consent.~* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure~Exclusion Criteria:~* Pregnant or lactating women~* Any factors that influence the usage of oral administration~* Central nervous system (CNS) metastasis~* One of the following conditions: non-controlled hypertension, coronary artery disease, arrhythmia and heart failure~* Abuse of alcohol or drugs~* Less than 4 weeks from the last clinical trial - Previous treatment with VEGFR inhibition~* Disability of serious uncontrolled intercurrence infection~* Proteinuria ≥ 2+ (1.0g/24hr)~* Evidence or a history of bleeding tendency within two months of the enrollment, regardless of seriousness~* History of artery/venous thromboembolic events in 12 months, such as cerebral vascular accident (including transient ischemic attack) etc.~* History of acute myocardial infarction, acute coronary syndrome or coronary artery bypass graft (CABG) in 6 months~* Bone fracture or wounds that was not cured for a long time~* Coagulation dysfunction, hemorrhagic tendency or receiving anticoagulant therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- treatment arm (Type: ACTIVE_COMPARATOR): treatment arm- subjects will receive Fruquintinib 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.
- control arm (Type: PLACEBO_COMPARATOR): control arm- subjects will receive Fruquintinib placebo 5mg orally, once daily (QD), plus BSC for 3 wks on/ 1 wk off. Patients will receive a cycles of 4 weeks of study treatment (1 cycle of study treatment includes 3 weeks of treatment and 1 week of drug discontinuation) or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).